139 related articles for article (PubMed ID: 8201596)
1. A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems.
Boruah RC; Skibo EB
J Med Chem; 1994 May; 37(11):1625-31. PubMed ID: 8201596
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
Islam I; Skibo EB; Dorr RT; Alberts DS
J Med Chem; 1991 Oct; 34(10):2954-61. PubMed ID: 1920349
[TBL] [Abstract][Full Text] [Related]
3. Chemistry of the pyrrolo[1,2-alpha]benzimidazole antitumor agents: influence of the 7-substituent on the ability to alkylate DNA and inhibit topoisomerase II.
Zhou R; Skibo EB
J Med Chem; 1996 Oct; 39(21):4321-31. PubMed ID: 8863809
[TBL] [Abstract][Full Text] [Related]
4. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.
Skibo EB; Xing C; Dorr RT
J Med Chem; 2001 Oct; 44(22):3545-62. PubMed ID: 11606119
[TBL] [Abstract][Full Text] [Related]
5. 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.
Jaffar M; Naylor MA; Robertson N; Lockyer SD; Phillips RM; Everett SA; Adams GE; Stratford IJ
Anticancer Drug Des; 1998 Mar; 13(2):105-23. PubMed ID: 9524554
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of benzimidazole-based DNA-cleaving agents. Comparison of benzimidazole, pyrrolobenzimidazole, and tetrahydropyridobenzimidazole analogues.
Skibo EB; Islam I; Heileman MJ; Schulz WG
J Med Chem; 1994 Jan; 37(1):78-92. PubMed ID: 8289204
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolo[1,2-a]benzimidazole-based aziridinyl quinones. A new class of DNA cleaving agent exhibiting G and A base specificity.
Skibo EB; Schulz WG
J Med Chem; 1993 Oct; 36(21):3050-5. PubMed ID: 8230090
[TBL] [Abstract][Full Text] [Related]
8. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
[TBL] [Abstract][Full Text] [Related]
9. First synthesis of an aziridinyl fused pyrrolo[1,2-a]benzimidazole and toxicity evaluation towards normal and breast cancer cell lines.
Bonham S; O'Donovan L; Carty MP; Aldabbagh F
Org Biomol Chem; 2011 Oct; 9(19):6700-6. PubMed ID: 21808774
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 6-aziridinylbenzimidazole derivatives and their in vitro antitumor activities.
Ahn CM; Kim SK; Han JL
Arch Pharm Res; 1998 Oct; 21(5):599-609. PubMed ID: 9875502
[TBL] [Abstract][Full Text] [Related]
11. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ
J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277
[TBL] [Abstract][Full Text] [Related]
12. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones.
Hargreaves RH; Hartley JA; Butler J
Front Biosci; 2000 Nov; 5():E172-80. PubMed ID: 11056081
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?
Robertson N; Stratford IJ; Houlbrook S; Carmichael J; Adams GE
Biochem Pharmacol; 1992 Aug; 44(3):409-12. PubMed ID: 1510692
[TBL] [Abstract][Full Text] [Related]
15. Chemistry and DNA alkylation reactions of aziridinyl quinones: development of an efficient alkylating agent of the phosphate backbone.
Skibo EB; Xing C
Biochemistry; 1998 Oct; 37(43):15199-213. PubMed ID: 9790684
[TBL] [Abstract][Full Text] [Related]
16. Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones.
Xing C; Wu P; Skibo EB; Dorr RT
J Med Chem; 2000 Feb; 43(3):457-66. PubMed ID: 10669573
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolobenzimidazoles linked to heterocycles and peptides. Design of DNA base pair specific phosphate hydrolyzing agents and novel cytotoxic agents.
Ghodousi A; Huang X; Cheng Z; Skibo EB
J Med Chem; 2004 Jan; 47(1):90-100. PubMed ID: 14695823
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
19. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase.
Phillips RM
Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of EO9 anti-tumour activity by hydralazine.
Bibby MC; Sleigh NR; Loadman PM; Double JA
Eur J Cancer; 1993; 29A(7):1033-5. PubMed ID: 8499134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
